What’s News in Markets: Banking Boom, Macy’s Troubles, Drugmakers Slide - WSJ What’s News

Summary4 min read

WSJ What’s News in Markets: Banking Boom, Macy’s Troubles, Drugmakers Slide
Released on January 18, 2025

Host: Francesca Fontana
Produced by: Pierre Bienime and Taliar Bell

Market Performance Overview

In this episode of What’s News in Markets, Francesca Fontana provides a comprehensive analysis of the week's stock market movements, highlighting significant gains and declines across various sectors. The major indices closed the week on a high note, marking their best performance since the post-election rally in November.

Weekly Gains:
- Dow Jones Industrial Average: Increased by 3.7%
- S&P 500: Rose by 2.9%
- Nasdaq Composite: Gained 2.5%

Francesca notes, “[...] the Dow, S&P 500, and Nasdaq all had their best trading day since that big post-election rally back in November” (00:45). These gains were largely driven by optimistic inflation data suggesting potential rate cuts and robust earnings reports from major banks.

Banking Sector Booms

The banking sector stood out with remarkable quarterly profits, signaling strong investor confidence and a positive economic outlook influenced by the incoming Trump administration.

Key Bank Performances:
- JPMorgan Chase: Net income surged by 50%.
- Goldman Sachs: Net income more than doubled.
- Citigroup: Swung to a profit after previous losses.
- Wells Fargo, Morgan Stanley, and Bank of America: Also reported strong profit growth.

Francesca attributes the banks' success to heightened optimism from corporate clients regarding economic prospects and a resurgence in deal-making, fundraising, and trading activities: “...banks are seeing this optimism from their corporate clients about the economy and the incoming Trump administration, which is spurring a big return to deal making, fundraising and trading” (02:15).

Stock Performance:
- Goldman Sachs: Up nearly 12% for the week.
- Wells Fargo: Rose over 10%.
- Citigroup: Increased by 12%.

These gains underscore the market’s positive reception of the banks' financial health and future prospects.

Retail Sector Challenges: Macy’s vs. Target

While the overall retail landscape showed a 4% increase in core sales during November and December compared to 2023, not all retailers fared equally.

Macy’s Struggles:
- Performance: Macy's warned of weaker holiday sales despite efforts to boost revenue.
- Stock Impact: Shares tumbled 8.1% on Monday and dropped over 11% for the week.
- Insight: “Despite the company's recent efforts to boost revenue and turn the company around, Macy's shares tumbled” (04:10).
Target’s Mixed Results:
- Performance: Reported better-than-expected sales during the holiday period after years of sluggish performance.
- Stock Impact: Despite strong sales, shares slipped 1% on Thursday and fell 5.7% for the week.
- Insight: “Even so, Target shares slipped 1% Thursday and on a weekly basis fell 5.7%” (05:20).

Francesca explains that while consumer spending remained robust, certain strategic missteps or market expectations affected stock performance differently across retailers.

Drugmakers Face Slumps

The pharmaceutical sector experienced notable declines, with major drugmakers reporting disappointing earnings and guidance.

Moderna's Decline:
- Earnings Report: Missed Wall Street’s expectations with a revised 2025 revenue forecast slashed from $3.5 billion to between $1.5 billion and $2.5 billion due to sluggish sales of Covid and RSV vaccines.
- Stock Impact: Shares plunged 17% on Monday and fell 19% for the week.
- Quote: “Moderna really slashed this forecast” (06:45).
Eli Lilly's Warning:
- Issue: Sales growth of diabetes and anti-obesity drugs Mounjaro and Zepbound slower than anticipated.
- Stock Impact: Shares sold off over 6% on Tuesday and dropped more than 9% for the week.
Novo Nordisk's Setback:
- Issue: Both Novo Nordisk and Eli Lilly faced further declines after the U.S. Government announced that Wegovy and Ozempic would undergo a second round of Medicare price negotiations, potentially hindering sales growth.
- Stock Impact: Novo Nordisk shares fell 4.1% on Thursday and over 8% for the week.

Francesca highlights, “Now, it wasn't just me who was under the weather this week. So were some of the big names in drugmaker stocks” (07:30), emphasizing the sector-wide challenges stemming from regulatory pressures and shifting market dynamics.

Conclusion

Francesca Fontana wraps up the episode by directing listeners to her column in the Wall Street Journal’s Exchange section for more detailed insights on stock movements influenced by the week's news. She emphasizes the importance of staying informed and maintaining a diversified investment portfolio to navigate the ever-changing market landscape.

“Have a great weekend, stay healthy and see you next Saturday,” Francesca signs off, underscoring the cyclical nature of market news and the need for continuous engagement (08:15).

Key Takeaways:

Banking Sector: Strong profit reports driven by economic optimism and strategic business activities.
Retail Sector: Mixed performance with Macy’s struggling despite overall retail growth, while Target showed resilience.
Pharmaceutical Sector: Significant challenges due to lowered revenue forecasts and regulatory pressures impacting major drugmakers.

For a deeper dive into these topics and to explore more stock movements influenced by the week's news, visit Francesca Fontana’s column in the Wall Street Journal’s Exchange section.

Loading summary

Transcript2 lines

[00:01]
A
Would you wear the same shoes for every occasion or rock the same outfit seven days a week? Of course not. Your style is better with options. Your investments could be too. CBOE Index options give you access to various contract sizes, global trading hours and potential tax advantages. That's a good look for any portfolio. If you're ready to invest in style, head to betterwithoptions.com There are risks associated with CBOE company products. Review the disclosures and disclaimers@cboe.com USDISCLAIMERS.
[00:33]
B
Hey listeners, it's Saturday, January 18th. I'm Francesca Fontana for the Wall Street Journal and this is what's News in Markets, our look at the biggest stock moves of the week and the news that drove them. Let's get to it. Welcome back everybody, and apologies in advance for any hoarseness on my part. I'm getting over being under the weather thanks to the frigid temperatures we've been having here in New York. And yes, I had a cold, but stocks were red hot this week most on Wednesday, the dow S&P 500 and NASDAQ all had their best trading day since the big post election rally back in November thanks to new inflation data that's been stoking optimism for rate cuts and big banks setting a strong tone for earnings season. More on that in a second, but in came the cold. On Thursday, all three indexes ended lower, weighed down by declines in tech stocks. But on Friday, stocks warmed right back up and the major indexes notched their best week since that post election rally. On a weekly basis, The Dow gained 3.7%, the S&P 500 added 2.9% and the Nasdaq rose 2.5%. Let's circle back to those big banks, which posted surging quarterly profits on Wednesday thanks to a rebound on Wall Street. JPMorgan Chase said its net income rose 50% while Goldman Sachs said its net income more than doubled and Citigroup swung to a profit. We got similar readings from other big players this week too, like Wells Fargo, Morgan Stanley and Bank of America. Why the totally gangbusters numbers? Because for one, banks are seeing this optimism from their corporate clients about the economy and the incoming Trump administration, which is spurring a big return to deal making, fundraising and trading. So how'd the stocks do? Well, Goldman, Wells Fargo and Citi saw their stocks each close at least 6% higher on Wednesday, with Goldman ranking among the top performers in the Dow. And on the week, Goldman gained nearly 12%, Wells Fargo rose more than 10% and Citi added 12% not all retailers had a holly, jolly holiday season in 2024. Now, that's not to say shoppers weren't busy. They were, and I have data to prove it. During November and December, core retail sales increased 4% from 2023, per the Commerce Department. But some companies didn't get as much demand as they expected, for instance, Macy's. So on Monday, the department store chain warned of weaker holiday sales. Despite the company's recent efforts to boost revenue and turn the company around. Macy's shares tumbled 8.1% Monday and on a weekly basis lost more than 11%. Meanwhile, Target had good holiday sales, but you wouldn't know that from its stock move on Thursday. After years of sluggish sales, the big box giant reported better than expected sales in the all important holiday period. But even so, Target shares slipped 1% Thursday and on a weekly basis fell 5.7%. Last but not least, it wasn't just me who was under the weather this week. So were some of the big names in drugmaker stocks. Now let's start with Moderna, whose shares took a nosedive after its latest earnings report. Notably, the biotech company's 2025 revenue guidance missed Wall Street's expectations. And Moderna really slashed this forecast. Before, the company had predicted full year revenue of up to $3.5 billion. Now it predicts 1.5 to 2.5 billion as sales of its Covid and RSV vaccines remain sluggish. Shares plunged 17% on Monday, and on a weekly basis the stock lost 19%. Then there was Eli Lilly, which on Tuesday warned that sales of its popular diabetes and anti obesity drugs Mounjaro and Zepbound were growing slower than anticipated, citing the lower than expected inventory of the drugs. Lilly's shares ended up selling off more than 6% on Tuesday and U.S. traded shares of rival Novo Nordisk. Ozempic, anyone? That's the company that makes it dropped 4.1%. Then on Friday, both stocks notched daily losses again after the US Government said that Wegovy and Ozempic were on a list of drugs subject to a second round of Medicare price negotiations, which could potentially dent the drug's sales growth. And on the week, Lilly ended more than 9% lower and Novo Nordisk ended more than 8% lower. And now you know what's news in markets this week. You can read about more stocks that moved on the week's news in the Score, my column in the Wall Street Journal's Exchange section. Today's show was produced by Pierre Bienime, with supervising producer Taliar Bell. I'm Francesca Fontana. Have a great weekend, stay healthy and see you next Saturday.